COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

Computational Omics Pre-Awardees

The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) is pleased to announce the pre-awardees of the Computational Omics solicitation. Working with NVIDIA Foundation's Compute the Cure initiative and Leidos Biomedical Research Inc., the NCI, through this solicitation, seeks to leverage computational efforts to provide tools for the mining and interpretation of large-scale publicly available ‘omics’ datasets. The objectives of this project are to provide tools that will enable the integration, analysis, and visualization of large-scale publicly available omics datasets.

Leidos Biomedical will be negotiating awards with the following Offerors:

Columbia University

  • Dr. Andrea Califano, Dr. Aris Floratos
  • "Reverse engineering cell models of master regulator genes"

The Ohio State University

  • Dr. Kun Huang
  • "Bio-imaging tools for multi-omic data visualization"

Vanderbilt University

  • Dr. Bing Zhang
  • "Constructing molecular networks via novel pairwise associations"

"Compute the Cure" is a strategic philanthropic initiative of the NVIDIA Foundation that aims to advance the fight against cancer by supporting cancer researchers in their search for a cure. Under this initiative, the NVIDIA Foundation has also selected two computational omics proposals for funding:

Dana-Farber Cancer Institute

  • Dr. John Quackenbush
  • "Advanced data mining to discover disease subtypes in cancer"

Stanford University

  • Dr. Vijay Pande
  • "Personalized tumor diagnostics through large-scale deep learning and all-atom simulation"

While the NCI’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) supports similar goals and objectives as Compute the Cure, the NCI is not providing support to NVIDIA Foundation for this initiative or endorsing the Foundation’s activities.